Pacira Biosciences Inc

PCRX remains in a Stage 2 advance with an active Momentum Breakout clearing the consolidation high, and EMAs aligned bullishly. Price is tracking above rising 9/20/50 EMAs with RSI supportive, validating near-term participation. Execution favors buying shallow pullbacks into the 20-day EMA near recent support. Primary risks include overhead resistance at the prior swing high and a decisive close below the 50-day SMA.

• ↑Q2 revenue reached $192.4 M (+6% YoY) with adjusted EBITDA of $48.7 M
• ↑Exparel now covers over 150 M lives, widening U.S. market access
• ↓Elective surgery volumes sensitive to macroeconomic swings, slowing growth